PNC Financial Services Group
OCUL icon

PNC Financial Services Group’s Ocular Therapeutix OCUL Stock Holding History

PNC Financial Services Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.4K Buy
957
+348
+57% +$3.15K ﹤0.01% 4117
2026
Q1 		$5.16K Sell
609
-73
-11% -$696 ﹤0.01% 4253
2025
Q4 		$8.28K Sell
682
-44
-6% -$534 ﹤0.01% 4038
2025
Q3 		$8.49K Buy
726
+215
+42% +$2.57K ﹤0.01% 4007
2025
Q2 		$4.74K Buy
511
+228
+81% +$1.78K ﹤0.01% 4156
2025
Q1 		$2.07K Buy
+283
New +$2.17K ﹤0.01% 4331
2024
Q3 		– Sell
-106
Closed -$725 – 4873
2024
Q2 		$725 Sell
106
-16
-13% -$99 ﹤0.01% 4481
2024
Q1 		$1.11K Buy
122
+111
+1,009% +$788 ﹤0.01% 4345
2023
Q4 		$49 Buy
+11
New +$33 ﹤0.01% 4566
2022
Q1 		– Sell
-1,000
Closed -$7K – 4652
2021
Q4 		$7K Buy
+1,000
New +$7.77K ﹤0.01% 3883
2018
Q3 		– Sell
-1,500
Closed -$10K – 4203
2018
Q2 		$10K Buy
+1,500
New +$10.3K ﹤0.01% 3687

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PNC Financial Services Group's OCUL Position: Q2 2026 in Review

PNC Financial Services Group increased its Ocular Therapeutix (OCUL) stake by 57% in Q2 2026, buying an estimated $3.15K and bringing the position to 957 shares worth $9.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4117.

PNC Financial Services Group first reported a position in OCUL in Q2 2018 and has held it in 11 quarters since. The position peaked at $10K in Q2 2018. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • PNC Financial Services Group held 957 shares of Ocular Therapeutix worth $9.4K as of Q2 2026.
  • PNC Financial Services Group bought 348 Ocular Therapeutix shares in Q2 2026, an estimated $3.15K.
  • Ocular Therapeutix made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4117 holding.
  • PNC Financial Services Group first reported a position in Ocular Therapeutix in Q2 2018 and has held it in 11 quarters since.
  • PNC Financial Services Group's Ocular Therapeutix position peaked at $10K in Q2 2018.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.